Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB Operating Cash Flow
Cash generated by the company's core business operations during the period.
Nuvation Bio Inc.NYSE: NUVB
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow declines year over year
Q2 FY2026 operating cash flow of $5.07M (cash outflow) fell 89.5% year over year, behind the -50.9% change in trailing-twelve-month operating cash flow. Over 3 fiscal years it compounded at +21.7% a year.
Context
- Operating cash flow amounted to 275.7% of revenue in FY2025, down 1380.7 pp from a year earlier.
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -89.5% toward the trailing-twelve-month pace of -50.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (173.43M) USD
- Year-over-year change
- -33.0%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (173.43M) | -33.0% |
| FY2024 | 2024-12-31 | (130.41M) | -91.8% |
| FY2023 | 2023-12-31 | (68M) | +29.2% |
| FY2022 | 2022-12-31 | (96.11M) | -40.9% |
| FY2021 | 2021-12-31 | (68.19M) | — |
Operating Cash Flow vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 operating cash flow of $82.62M is the 9th largest of the 11 companies compared; the peer median is $203.45M.
- Its year-over-year change of -50.9% is the lowest of 11, against a peer median of +46.6%.
- Operating cash flow amounts to 48.6% of revenue for NUVB, versus a peer median of 434.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $338.65M | +82.8% | +52.8% | — | |
| LTM Jun 2026 | $333.34M | +7.9% | +43.3% | 468.7% | |
| LTM Sep 2026 | $251.97M | +40.4% | +26.7% | 224975.9% | |
| LTM Mar 2026 | $226.21M | +55.5% | +50.9% | 434.7% | |
| LTM Jun 2026 | $205.01M | +25.8% | +68.9% | — | |
| LTM Sep 2026 | $201.9M | +52.7% | +39.8% | — | |
| LTM Jun 2026 | $173.75M | +87.5% | — | 55.8% | |
| LTM Mar 2026 | $172.11M | +3.5% | +7.1% | 951.2% | |
| LTM Jun 2026 | $82.62M | -50.9% | +21.7% | 48.6% | |
| LTM Mar 2026 | $77.55M | +68.6% | +24.2% | 358.8% | |
| LTM Sep 2026 | $75.22M | -28.1% | — | 110.8% | |
| Peer median (excluding NUVB) | $203.45M | +46.6% | +41.6% | 434.7% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.27M | 16.29M | 19.51M | 32.28M | 35.89M |
| Change in Working Capital | 4.79M | (3.45M) | 540K | (12.51M) | (11.98M) |
| Accounts Receivables | (1.95M) | 554K | (1.22M) | (12.59M) | (3.07M) |
| Inventory | 0 | 0 | 0 | 0 | (11.41M) |
| Accounts Payables | 1.86M | (1.79M) | 70K | (1.65M) | 3.13M |
| Other Working Capital | 4.88M | (2.22M) | 1.69M | 1.74M | (630K) |
| Other Non-Cash Items | 4.41M | (4.95M) | (12.47M) | 417.08M | 5.55M |
| Operating Cash Flow | (68.19M) | (96.11M) | (68M) | (130.41M) | (173.43M) |
| Capital Expenditures | (282K) | (370K) | (69K) | (162K) | (354K) |
| Acquisitions (Net) | 0 | 0 | 0 | 12.43M | 0 |
| Purchases of Investments | (609.3M) | (520.31M) | (703.37M) | (339.65M) | (354.42M) |
| Sales of Investments | 154.91M | 584.12M | 712.35M | 450.08M | 462.29M |
| Other Investing Activities | 0 | 13K | 14K | 0 | 0 |
| Investing Cash Flow | (454.67M) | 63.46M | 8.92M | 122.7M | 99.52M |
| Debt Repayment | 0 | 0 | 0 | (4.55M) | 191.11M |
| Common Stock Issued | 0 | 0 | 0 | 4.89M | 11.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 625.53M | 1.33M | 628K | 0 | 0 |
| Financing Cash Flow | 625.53M | 1.33M | 628K | 331K | 202.54M |
| Effect of Forex Changes | 0 | 0 | 0 | 453K | (265K) |
| Net Change in Cash | 102.67M | (31.32M) | (58.45M) | (6.93M) | 128.36M |
| Free Cash Flow | (68.47M) | (96.48M) | (68.07M) | (130.58M) | (173.78M) |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.